Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection
Ragab, A., Abdallah, S., Shiha, G., Ismail, H., Albnnan, M., El-Desouky, M. (2022). Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection. EKB Journal Management System, 65(9), 93-98. doi: 10.21608/ejchem.2022.109105.4994
Abdallah A. Ragab; Sanaa O. Abdallah; Gamal Shiha; Hisham Ismail; Mohamed S. Albnnan; Mohamed Aly El-Desouky. "Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection". EKB Journal Management System, 65, 9, 2022, 93-98. doi: 10.21608/ejchem.2022.109105.4994
Ragab, A., Abdallah, S., Shiha, G., Ismail, H., Albnnan, M., El-Desouky, M. (2022). 'Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection', EKB Journal Management System, 65(9), pp. 93-98. doi: 10.21608/ejchem.2022.109105.4994
Ragab, A., Abdallah, S., Shiha, G., Ismail, H., Albnnan, M., El-Desouky, M. Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection. EKB Journal Management System, 2022; 65(9): 93-98. doi: 10.21608/ejchem.2022.109105.4994

Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection

Egyptian Journal of Chemistry
Article 9, Volume 65, Issue 9, September 2022, Page 93-98  XML PDF (252.87 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2022.109105.4994
View on SCiNiTO View on SCiNiTO
Authors
Abdallah A. Ragab1; Sanaa O. Abdallah1; Gamal Shiha2; Hisham Ismailorcid 3; Mohamed S. Albnnan4; Mohamed Aly El-Desouky email orcid 5
1Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt
2Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
3Biochemistry department, Faculty of Science, Minia University
4Biotechnology Research Center, New Dameitta 34517, Egypt
5Biochemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt
Abstract
The goal of this study was to determine cartilage oligomeric matrix protein (COMP) levels as a biochemical marker in various phases of hepatic fibrosis and to estimate its effectiveness for hepatic fibrosis monitoring. Eighty-eight patients with various stages of hepatic fibrosis were enrolled in this trial, all of whom had a sustained virological response after using direct-acting antivirals. Patients were followed-up after one year of treatment. FibroScan and COMP were determined before and after one year from the end of treatment. Liver enzymes such as alanine transaminase, aspartate transaminase, and alkaline phosphatase were measured in addition to albumin, total bilirubin, creatinine, and glucose. COMP levels increased with the progression of liver fibrosis, according to our findings. COMP enabled the correct identification of F2-F4, F3-F4 and F4 with areas under the curve of 0.765, 0.788 and 0.790, respectively. Our findings showed that 68.4%, 87.1%, and 98.6% of F4, F3-F4, and F4, respectively, were positive for COMP. Notably, the vast majority of individuals who tested positive for COMP were appropriately classified. In conclusion, this work provides a promising marker that might be used as a potential serologic biomarker for liver fibrosis staging and may facilitate definitive therapy as well as a complementary diagnostic tool in monitoring cirrhotic patients for detection of early HCC.
Keywords
Liver fibrosis; Cirrhosis; COMP; Liver enzymes, Diagnosis
Statistics
Article View: 526
PDF Download: 165